Compare BioNano Genomics Inc (BNGO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.33 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 3429× BioNano Genomics Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | TTWO | |
|---|---|---|
Market Cap | $13.66M | $46.84B |
Sector | Health | Media |
52-Week High | $4.92 | $262.29 |
52-Week Low | $1.06 | $189.69 |
Enterprise Value | $16.26M | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Take-Two Interactive (TTWO) trades at $243.60, down 3.93% over 24 hours, with a bullish technical signal from moving averages and support near $240. The company reported Q1 2026 EPS of $0.80, beating estimates, but faces fundamental challenges with a net income margin of -4.79% and negative ROE of -9.04%. Recent news highlights strong GTA VI pre-orders as a key catalyst, with FY2027 net bookings guidance maintained at $8-$8.2 billion (company earnings report, August 7, 2026).
Outlook is optimistic due to GTA VI's November 2026 launch potential, but risks include high debt levels (debt-to-asset ratio of 39.87% in 2025) and consistent net losses. Analyst consensus is strongly bullish with a $300.55 price target, suggesting 23% upside from current levels if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
